P. Axelsson

Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial.

P. Sonneveld, A. Waage, N. Abildgaard, 2018, Haematologica.

Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group

H. Nahi, T. Klausen, A. Waage, 2021, European journal of haematology.

A Prospective Phase 2 Study to Assess Minimal Residual Disease after Ixazomib, Lenalidomide and Dexamethasone Treatment for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

H. Nahi, A. Waage, M. Hansson, 2020 .

A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group

O. Linder, H. Nahi, A. Vangsted, 2019, Blood.

Carfilzomib and dexamethasone maintenance prolong time to progression following salvage ASCT in multiple myeloma

O. Linder, H. Nahi, A. Vangsted, 2019 .

Isodicentric 7p, idic(7)(q11.2), in acute myeloid leukemia associated with older age and favorable response to induction chemotherapy: A new clinical entity?

H. Tanke, B. Johansson, F. Mitelman, 2001, Genes, chromosomes & cancer.

Idelalisib (PI3Kδ inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: A Swedish nation‐wide real‐world report on consecutively identified patients

H. Johansson, A. Österborg, B. Lauri, 2023, European journal of haematology.